Alaunos Therapeutics, Inc. - Understand $tcrt stock

$TCRT Market Cap: $3.875 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$6.000K

TTM

Gross Margin

Net Earnings

-$11.78M

TTM

Current Assets

$3.550M

Q3 2024

Current Liabilities

$826.0K

Q3 2024

Current Ratio

429.78%

Q3 2024

Total Assets

$3.550M

Q3 2024

Total Liabilities

$826.0K

Q3 2024

Book Value

$2.724M

Q3 2024

Cash

$1.683M

Q3 2024

P/E

-0.3289

Nov 29, 2024 EST

Free Cash Flow

-$11.76M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Revenue	$5.000K	$2.900M	$0.00	$0.00	$0.00	$146.0K	$15.90M	$6.861M	$4.330M	$1.370M	$800.0K	$800.0K	$667.0K		$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-99.83%				-100.0%	-99.08%	131.74%	58.45%	216.06%	71.25%	0.0%	19.94%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2009	2008	2007	2006	2005	2004
Revenue	$5.000K	$2.900M	$0.00	$0.00	$0.00	$146.0K	$15.90M	$6.861M	$4.330M	$1.370M	$800.0K	$800.0K	$667.0K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Selling, General & Admin	$12.22M	$13.14M	$27.56M	$27.67M	$19.53M	$19.92M	$14.80M	$14.38M	$17.65M	$12.17M	$15.66M	$19.52M	$14.98M	$11.64M	$7.570M	$8.370M	$9.580M	$8.720M	$4.190M	$3.580M
YoY Change	-7.02%	-52.32%	-0.37%	41.68%	-1.96%	34.6%	2.93%	-18.54%	45.03%	-22.29%	-19.77%	30.31%	28.69%	53.76%	-9.56%	-12.63%	9.86%	108.11%	17.04%
% of Gross Profit
Research & Development	$16.28M	$25.02M	$49.64M	$52.70M	$38.33M	$34.13M	$45.08M	$157.8M	$106.8M	$32.71M	$42.85M	$83.45M	$57.08M	$12.91M	$4.560M	$17.25M	$18.99M	$10.39M	$5.590M	$2.130M
YoY Change	-34.93%	-49.6%	-5.79%	37.48%	12.3%	-24.29%	-71.43%	47.77%	226.5%	-23.68%	-48.65%	46.18%	342.16%	183.11%	-73.57%	-9.16%	82.77%	85.87%	162.44%
% of Gross Profit
Depreciation & Amortization	$2.315M	$2.800M	$2.600M	$1.100M	$629.0K	$575.0K	$369.0K	$290.0K	$357.0K	$460.0K	$740.0K	$660.0K	$270.0K	$190.0K	$330.0K	$390.0K	$430.0K	$170.0K	$100.0K	$30.00K
YoY Change	-17.32%	7.69%	136.36%	74.88%	9.39%	55.83%	27.24%	-18.77%	-22.39%	-37.84%	12.12%	144.44%	42.11%	-42.42%	-15.38%	-9.3%	152.94%	70.0%	233.33%
% of Gross Profit
Operating Expenses	$28.50M	$38.03M	$77.95M	$80.36M	$57.86M	$54.05M	$59.88M	$157.8M	$106.8M	$32.71M	$42.85M	$83.45M	$57.08M	$12.91M	$12.12M	$25.62M	$28.57M	$19.11M	$9.790M	$5.710M
YoY Change	-25.06%	-51.21%	-3.0%	38.89%	7.04%	-9.74%	-62.05%	47.77%	226.5%	-23.68%	-48.65%	46.18%	342.16%	6.52%	-52.69%	-10.33%	49.5%	95.2%	71.45%
Operating Profit	-$34.27M	-$35.11M	-$77.55M	-$80.36M	-$57.86M	-$53.91M	-$53.49M	-$165.3M	-$120.1M	-$43.50M	-$57.71M	-$102.2M	-$71.40M	-$24.55M
YoY Change	-2.39%	-54.73%	-3.5%	38.89%	7.33%	0.77%	-67.64%	37.64%	176.1%	-24.63%	-43.51%	43.09%	190.88%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Interest Expense	-$1.921M	$3.154M	-$1.182M		$0.00	$158.0K	-$1.295M	-$124.0K	$0.00	$11.72M	$1.190M	$6.050M	$7.580M	-$8.890M	$4.460M	$390.0K	$1.960M	$1.260M	$270.0K	$20.00K
YoY Change	-160.91%	-366.84%			-100.0%	-112.2%	944.35%		-100.0%	884.87%	-80.33%	-20.18%	-185.26%	-299.33%	1043.59%	-80.1%	55.56%	366.67%	1250.0%
% of Operating Profit
Other Income/Expense, Net	$1.048M	-$2.625M	-$1.202M	$385.0K	$813.0K	$631.0K	$465.0K	$134.0K	$12.00K	-$5.000K	-$579.0K	-$13.00K	$39.00K	$765.0K	$10.00K
YoY Change	-139.92%	118.39%	-412.21%	-52.64%	28.84%	35.7%	247.01%	1016.67%	-340.0%	-99.14%	4353.85%	-133.33%	-94.9%	7550.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Pretax Income	-$35.14M	-$37.73M	-$78.75M	-$79.98M	-$117.8M	-$53.12M	-$54.32M	-$165.3M	-$120.1M	-$31.78M	-$57.11M	-$96.13M	-$63.78M	-$32.67M	-$7.650M	-$25.23M	-$26.61M	-$17.86M	-$9.520M	-$5.690M
YoY Change	-6.86%	-52.09%	-1.53%	-32.11%	121.77%	-2.22%	-67.14%	37.64%	277.88%	-44.35%	-40.59%	50.72%	95.22%	327.06%	-69.68%	-5.19%	48.99%	87.61%	67.31%
Income Tax											$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$35.14M	-$37.73M	-$78.75M	-$79.98M	-$117.8M	-$53.12M	-$54.32M	-$165.3M	-$120.1M	-$31.78M	-$57.11M	-$96.13M	-$63.78M	-$32.67M	-$7.649M	-$25.23M	-$26.61M	-$17.86M	-$9.517M	-$5.687M
YoY Change	-6.86%	-52.09%	-1.53%	-32.11%	121.77%	-2.22%	-67.14%	37.65%	277.86%	-44.35%	-40.6%	50.73%	95.22%	327.11%	-69.68%	-5.18%	49.01%	87.63%	67.35%
Net Earnings / Revenue	-702800.0%	-1301.03%				-36381.51%	-341.65%	-2409.23%	-2773.39%	-2319.78%	-7138.38%	-12016.5%	-9561.92%
Basic Earnings Per Share	-$2.20	-$0.17	-$0.37		-$0.70	$0.96	-$0.53	-$1.32
Diluted Earnings Per Share	-$2.20	-$0.17	-$367.3K	-$381.5K	-$0.70	$0.96	-$0.53	-$1.32	-$0.96	-$0.31	-$0.66	-$1.22	-$0.97	-$0.71	-$0.33	-$1.19	-$1.41	-$1.42	-$1.23	-$0.73

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004
Cash & Short-Term Investments	$6.062M	$39.06M	$76.05M	$115.1M	$79.74M	$61.73M	$70.95M	$81.05M	$140.7M	$42.80M	$68.20M	$73.30M	$104.7M	$60.40M	$48.80M	$11.40M	$35.00M	$28.40M	$8.900M	$1.000M
YoY Change	-84.48%	-48.64%	-33.91%	44.3%	29.18%	-12.99%	-12.47%	-42.39%	228.74%	-37.24%	-6.96%	-29.99%	73.34%	23.77%	328.07%	-67.43%	23.24%	219.1%	790.0%
Cash & Equivalents	$6.062M	$39.06M	$76.05M	$115.1M	$79.74M	$61.73M	$70.95M	$81.05M	$140.7M	$42.80M	$68.20M	$73.30M	$104.7M	$60.40M	$48.80M	$11.40M	$35.00M	$26.90M	$8.900M	$1.000M
Short-Term Investments																	$0.00	$1.600M	$0.00
Other Short-Term Assets	$2.198M	$14.74M	$1.666M	$10.86M	$22.42M	$20.69M	$19.82M	$23.81M	$11.40M	$1.100M	$1.900M	$6.900M	$1.300M	$400.0K	$400.0K	$300.0K	$500.0K	$500.0K	$200.0K	$100.0K
YoY Change	-85.09%	784.57%	-84.65%	-51.59%	8.36%	4.41%	-16.77%	108.86%	936.36%	-42.11%	-72.46%	430.77%	225.0%	0.0%	33.33%	-40.0%	0.0%	150.0%	100.0%
Inventory
Prepaid Expenses
Receivables	$1.000K	$4.000K	$1.111M	$4.665M	$3.330M	$1.864M	$19.00K	$21.00K	$400.0K	$100.0K	$100.0K	$100.0K	$100.0K
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$8.261M	$53.80M	$78.83M	$130.6M	$105.5M	$84.29M	$90.78M	$104.9M	$152.5M	$44.10M	$70.30M	$80.30M	$106.1M	$60.80M	$49.20M	$11.70M	$35.50M	$28.90M	$9.100M	$1.100M
YoY Change	-84.64%	-31.75%	-39.63%	23.79%	25.16%	-7.16%	-13.44%	-31.22%	245.8%	-37.27%	-12.45%	-24.32%	74.51%	23.58%	320.51%	-67.04%	22.84%	217.58%	727.27%
Property, Plant & Equipment	$2.000K	$10.60M	$15.36M	$14.88M	$3.382M	$1.097M	$1.211M	$843.0K	$600.0K	$500.0K	$800.0K	$2.000M	$1.100M	$300.0K	$300.0K	$500.0K	$700.0K	$500.0K	$300.0K	$200.0K
YoY Change	-99.98%	-31.02%	3.23%	340.01%	208.3%	-9.41%	43.65%	40.5%	20.0%	-37.5%	-60.0%	81.82%	266.67%	0.0%	-40.0%	-28.57%	40.0%	66.67%	50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$542.0K	$673.0K	$875.0K	$240.0K	$9.669M	$13.61M	$621.0K	$600.0K	$600.0K	$700.0K	$1.100M	$900.0K	$500.0K	$300.0K	$400.0K	$500.0K	$200.0K	$100.0K	$100.0K
YoY Change	-100.0%	-19.47%	-23.09%	264.58%	-97.52%	-28.97%	2091.95%	3.5%	0.0%	-14.29%	-36.36%	22.22%	80.0%	66.67%	-25.0%	-20.0%	150.0%	100.0%	0.0%
Total Long-Term Assets	$2.000K	$11.14M	$16.03M	$15.76M	$3.622M	$10.77M	$14.82M	$1.464M	$1.200M	$1.100M	$1.500M	$3.100M	$2.000M	$700.0K	$500.0K	$900.0K	$1.200M	$600.0K	$400.0K	$300.0K
YoY Change	-99.98%	-30.54%	1.76%	335.01%	-66.36%	-27.37%	912.5%	22.0%	9.09%	-26.67%	-51.61%	55.0%	185.71%	40.0%	-44.44%	-25.0%	100.0%	50.0%	33.33%
Total Assets	$8.263M	$64.94M	$94.87M	$146.3M	$109.1M	$95.05M	$105.6M	$106.3M	$153.7M	$45.20M	$71.80M	$83.40M	$108.1M	$61.50M	$49.70M	$12.60M	$36.70M	$29.50M	$9.500M	$1.400M
YoY Change
Accounts Payable	$616.0K	$1.389M	$1.368M	$960.0K	$906.0K	$707.0K	$4.417M	$156.0K	$2.000M	$2.000M	$400.0K	$1.500M	$1.700M	$1.000M	$1.800M	$2.600M	$2.900M	$800.0K	$800.0K	$700.0K
YoY Change	-55.65%	1.54%	42.5%	5.96%	28.15%	-83.99%	2731.41%	-92.2%	0.0%	400.0%	-73.33%	-11.76%	70.0%	-44.44%	-30.77%	-10.34%	262.5%	0.0%	14.29%
Accrued Expenses	$1.340M	$6.012M	$6.805M	$17.41M	$11.62M	$8.763M	$9.909M	$9.109M	$8.900M	$7.200M	$6.400M	$16.50M	$10.80M	$2.500M	$1.300M	$3.100M	$3.400M	$2.200M	$1.400M	$900.0K
YoY Change	-77.71%	-11.65%	-60.91%	49.81%	32.6%	-11.57%	8.78%	2.35%	23.61%	12.5%	-61.21%	52.78%	332.0%	92.31%	-58.06%	-8.82%	54.55%	57.14%	55.56%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$16.77M	$7.868M
YoY Change	-100.0%	113.08%
Total Short-Term Liabilities	$1.956M	$24.17M	$16.04M	$18.37M	$12.53M	$9.483M	$20.86M	$15.81M	$18.10M	$10.80M	$7.800M	$18.90M	$13.40M	$3.600M	$3.100M	$5.800M	$6.300M	$2.900M	$2.300M	$1.600M
YoY Change	-91.91%	50.65%	-12.67%	46.64%	32.09%	-54.53%	31.92%	-12.66%	67.59%	38.46%	-58.73%	41.04%	272.22%	16.13%	-46.55%	-7.94%	117.24%	26.09%	43.75%
Long-Term Debt	$0.00	$0.00	$16.25M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$0.00	$2.216M	$4.517M	$3.995M	$1.578M	$4.000K	$37.56M	$42.52M	$48.20M	$600.0K	$14.60M	$16.10M	$23.10M	$27.40M	$18.50M	$100.0K	$100.0K	$0.00	$0.00	$0.00
YoY Change	-100.0%	-50.94%	13.07%	153.17%	39350.0%	-99.99%	-11.65%	-11.79%	7933.33%	-95.89%	-9.32%	-30.3%	-15.69%	48.11%	18400.0%	0.0%
Total Long-Term Liabilities	$0.00	$2.216M	$20.77M	$3.995M	$1.578M	$4.000K	$37.56M	$42.52M	$48.20M	$600.0K	$14.60M	$16.10M	$23.10M	$27.40M	$18.50M	$100.0K	$100.0K	$0.00	$0.00	$0.00
YoY Change	-100.0%	-89.33%	419.82%	153.17%	39350.0%	-99.99%	-11.65%	-11.79%	7933.33%	-95.89%	-9.32%	-30.3%	-15.69%	48.11%	18400.0%	0.0%
Total Liabilities	$1.956M	$26.38M	$36.81M	$22.36M	$14.10M	$9.487M	$58.42M	$58.33M	$66.40M	$11.40M	$22.40M	$35.00M	$36.50M	$31.00M	$21.60M	$5.800M	$6.400M	$3.000M	$2.300M	$1.600M
YoY Change	-92.59%	-28.33%	64.59%	58.56%	48.67%	-83.76%	0.16%	-12.16%	482.46%	-49.11%	-36.0%	-4.11%	17.74%	43.52%	272.41%	-9.38%	113.33%	30.43%	43.75%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016
Basic Shares Outstanding	16.00M	217.1M	214.4M	209.6M	168.0M	143.5M	136.9M	130.4M
Diluted Shares Outstanding	16.00M	217.1M	214.4M		168.0M	143.7M	136.9M	130.4M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $3.875 Million

About Alaunos Therapeutics, Inc.

Alaunos Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Houston, Texas and currently employs 1 full-time employees. The company went IPO on 2004-08-20. Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. The firm is focused on exploring strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. Separately, the Company is evaluating several potential in-licensing opportunities in obesity, oncology and virology.

Industry: Pharmaceutical Preparations Peers: 2seventy bio, Inc. ADMA BIOLOGICS, INC. Allakos Inc. Aura Biosciences, Inc. Entrada Therapeutics, Inc. Imago BioSciences, Inc. PRECIGEN, INC. Rallybio Corp